Phase 2 Trial of Oral Treatment for Ulcerative Colitis Now Recruiting

Phase 2 Trial of Oral Treatment for Ulcerative Colitis Now Recruiting
Lycera has announced the launch of a Phase 2 clinical trial to assess the effectiveness of its lead clinical-stage candidate, LYC-30937-EC (Enteric Coated), as a once daily oral treatment for patients with active ulcerative colitis (UC). The clinical trial is currently recruiting participants. “The initiation of the Phase 2 clinical trial of LYC-30937-EC is an important milestone in Lycera’s continued progress and is one of several clinical studies we plan to initiate in the second half of 2016 as we build our portfolio of novel immune modulatory treatments,” Paul Sekhri, Lycera’s president and chief executive officer, said in a press release. “Based upon the results of our preclinical and Phase 1 studies, we believe LYC-30937-EC may possess key advantages for patients, including localized therapy at the site of disease, and the potential for reduced systemic exposure and side effects," he added. LYC-30937-EC, a first-in-class, oral, gut-directed ATPase modulator, is designed to selectively target and induce apoptosis (cell death) in disease-causing immune cells (T-lymphocytes), while not affecting normal cells. Chronically activated and pathogenic T-lymphocytes have specific metabolic features that allow them to be targeted selectively by the drug candidate. Based on pre-clinical studies, LYC-30937-EC has therapeutic potential in inflammatory bowel diseases (IBDs) like UC, as well as in other autoimmune diseases. By being delivered directly to the gastrointestinal tract, LYC-30937-EC also
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *